论文部分内容阅读
目的:分析探讨瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂作用。方法:选择2013年4月~2014年9月来我院接受冠心病治疗的患者86例,将其按照年龄、性别等随机分为对照组和试验组,每组患者43例。对照组患者采用阿托伐他汀钙片治疗方式,试验组患者采用瑞舒伐他汀钙片治疗方式,治疗8周后比较两组患者的治疗效果。结果:试验组患者的总血清总胆固醇、低密度脂蛋白水平下降幅度明显优于对照组患者,两组患者比较差异显著,P<0.05具有统计学意义;试验组患者的低密度脂蛋白、总血清总胆固醇达标率均明显优于对照组患者,两组患者比较差异显著,P<0.05具有统计学意义;两组患者的三酰甘油、高密度脂蛋白、不良反应发生率情况比较差异不显著,P>0.05无统计学意义。结论:瑞舒伐他汀钙片治疗冠心病患者,临床治疗效果更为明显,不良反应发生率较低,值得临床推广应用。
Objective: To investigate the rosuvastatin and atorvastatin on patients with coronary heart disease lipid-regulating effect. Methods: From April 2013 to September 2014, 86 patients who received coronary heart disease in our hospital were selected and randomly divided into control group and experimental group according to their age and gender. There were 43 patients in each group. Patients in the control group were treated with atorvastatin calcium tablets. Patients in the test group were treated with rosuvastatin calcium tablets. The treatment effect was compared between the two groups after 8 weeks of treatment. Results: The total serum total cholesterol and low density lipoprotein levels in the experimental group decreased significantly compared with those in the control group. There was significant difference between the two groups (P <0.05). The LDL, Serum total cholesterol compliance rate was significantly better than the control group patients, two groups of patients was significantly different, P <0.05 was statistically significant; two groups of patients with triglyceride, high-density lipoprotein, the incidence of adverse reactions was not significantly different , P> 0.05 was not statistically significant. Conclusion: Rosuvastatin calcium tablets in patients with coronary heart disease, clinical treatment effect is more obvious, the incidence of adverse reactions is low, it is worthy of clinical application.